Catecholamine synthesis and metabolism in the central nervous system of mice lacking α 2-adrenoceptor subtypes: RESEARCH PAPER

British Journal of Pharmacology

Volumn 158, Issue 3, 2009, Pages 726-737

  Vieira Coelho, M A ^a,b   Serrao M P ^a   Afonso, J ^a   Pinto, C E ^a   Moura, E ^a,b  

^a University of Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

2 adrenoceptors; Aromatic L amino acid decarboxylase; Catechol O methyltransferase; Dopamine; L DOPA; Noradrenaline; Tyrosine hydroxylase

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2B ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; AMINE OXIDASE (FLAVIN CONTAINING); AROMATIC LEVO AMINO ACID DECARBOXYLASE; CATECHOL METHYLTRANSFERASE; CATECHOLAMINE; DOPA; DOPAMINE BETA MONOOXYGENASE; NORADRENALIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN LEVEL; CATECHOLAMINE METABOLISM; CATECHOLAMINE SYNTHESIS; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; ENZYME ACTIVITY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; VELOCITY; WILD TYPE;

ACRIDINES; ANIMALS; AROMATIC-L-AMINO-ACID DECARBOXYLASES; BIOLOGICAL TRANSPORT; BRAIN; CATECHOL O-METHYLTRANSFERASE; CATECHOLAMINES; CELL LINE, TUMOR; DOPAMINE BETA-HYDROXYLASE; HUMANS; LEVODOPA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOAMINE OXIDASE; PIPERAZINES; RECEPTORS, ADRENERGIC, ALPHA-2; TYROSINE 3-MONOOXYGENASE; YOHIMBINE;

EID: 70350055195     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00375.x     Document Type: Article

References (48)

1. Ahn NG, Klinman JP (1989). Nature of rate-limiting steps in a compartmentalized enzyme system. Quantitation of dopamine transport and hydroxylation rates in resealed chromaffin granule ghosts. J Biol Chem 264 (21 12259 12265.
2. Alexander SP, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd editionn. Br J Pharmacol 153 (Suppl. 2 S1 S209.
3. Altman JD, Trendelenburg AU, MacMillan L, Bernstein D, Limbird L, Starke K et al. (1999). Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice. Mol Pharmacol 56 (1 154 161.
4. del Amo EM, Urtti A, Yliperttula M (2008). Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci 35 (3 161 174.
5. Anden NE, Pauksens K, Svensson K (1982). Selective blockade of brain alpha 2-autoreceptors by yohimbine: effects on motor activity and on turnover of noradrenaline and dopamine. J Neural Transm 55 (2 111 120.
6. Baron BM, Siegel BW (1989). Alpha 2-adrenergic and muscarinic cholinergic receptors have opposing actions on cyclic AMP levels in SK-N-SH human neuroblastoma cells. J Neurochem 53 (2 602 609.
7. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 : 248 254.
8. Brede M, Nagy G, Philipp M, Sorensen JB, Lohse MJ, Hein L (2003). Differential control of adrenal and sympathetic catecholamine release by alpha 2-adrenoceptor subtypes. Mol Endocrinol 17 (8 1640 1646.
9. Bucheler MM, Hadamek K, Hein L (2002). Two alpha(2)-adrenergic receptor subtypes, alpha(2A) and alpha(2C), inhibit transmitter release in the brain of gene-targeted mice. Neuroscience 109 (4 819 826.
10. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP et al. (1994). International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46 (2 121 136.
11. Coge F, Krieger-Poullet M, Gros F, Thibault J (1990). Comparative and quantitative study of L-dopa decarboxylase mRNA in rat neuronal and non-neuronal tissues. Biochem Biophys Res Commun 170 (3 1006 1012.
12. Eisenhofer G, Kopin IJ, Goldstein DS (2004). Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 56 (3 331 349.
13. Fagerholm V, Rokka J, Nyman L, Sallinen J, Tiihonen J, Tupala E et al. (2008). Autoradiographic characterization of alpha(2C)-adrenoceptors in the human striatum. Synapse 62 (7 508 515.
14. Goldstein DS, Eisenhofer G, Kopin IJ (2003). Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther 305 (3 800 811.
15. Haapalinna A, Viitamaa T, MacDonald E, Savola JM, Tuomisto L, Virtanen R et al. (1997). Evaluation of the effects of a specific alpha 2-adrenoceptor antagonist, atipamezole, on alpha 1- and alpha 2-adrenoceptor subtype binding, brain neurochemistry and behaviour in comparison with yohimbine. Naunyn Schmiedebergs Arch Pharmacol 356 (5 570 582.
16. Haapalinna A, Leino T, Heinonen E (2003). The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats. Naunyn Schmiedebergs Arch Pharmacol 368 (5 342 351.
17. Hansson E, Ronnback L (1992). Adrenergic receptor regulation of amino acid neurotransmitter uptake in astrocytes. Brain Res Bull 29 (3-4 297 301.
18. Hashimoto W, Kitayama S, Kumagai K, Morioka N, Morita K, Dohi T (2005). Transport of dopamine and levodopa and their interaction in COS-7 cells heterologously expressing monoamine neurotransmitter transporters and in monoaminergic cell lines PC12 and SK-N-SH. Life Sci 76 (14 1603 1612.
19. Henry JP, Sagne C, Bedet C, Gasnier B (1998). The vesicular monoamine transporter: from chromaffin granule to brain. Neurochem Int 32 (3 227 246.
20. Hökfelt T, Fuxe K, Goldstein M (1973). Immunohistochemical localization of aromatic L-amino acid decarboxylase (DOPA decarboxylase) in central dopamine and 5-hydroxytryptamine nerve cell bodies of the rat. Brain Res 53 (1 175 180.
21. Huotari M, Santha M, Lucas LR, Karayiorgou M, Gogos JA, Mannisto PT (2002). Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice. J Pharmacol Exp Ther 303 (3 1309 1316.
22. Kumer SC, Vrana KE (1996). Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 67 (2 443 462.
23. Lahdesmaki J, Sallinen J, MacDonald E, Sirvio J, Scheinin M (2003). Alpha2-adrenergic drug effects on brain monoamines, locomotion, and body temperature are largely abolished in mice lacking the alpha2A-adrenoceptor subtype. Neuropharmacology 44 (7 882 892.
24. Lew JY, Garcia-Espana A, Lee KY, Carr KD, Goldstein M, Haycock JW et al. (1999). Increased site-specific phosphorylation of tyrosine hydroxylase accompanies stimulation of enzymatic activity induced by cessation of dopamine neuronal activity. Mol Pharmacol 55 (2 202 209.
25. Lindgren N, Xu ZQ, Lindskog M, Herrera-Marschitz M, Goiny M, Haycock J et al. (2000). Regulation of tyrosine hydroxylase activity and phosphorylation at Ser(19) and Ser(40) via activation of glutamate NMDA receptors in rat striatum. J Neurochem 74 (6 2470 2477.
26. Lindgren N, Xu ZQ, Herrera-Marschitz M, Haycock J, Hokfelt T, Fisone G (2001). Dopamine D(2) receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum. Eur J Neurosci 13 (4 773 780.
27. Link RE, Desai K, Hein L, Stevens ME, Chruscinski A, Bernstein D et al. (1996). Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c. Science 273 (5276 803 805.
28. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I et al. (1995). Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34 (13 4202 4210.
29. Matsui H, Kato T, Yamamoto C, Fujita K, Nagatsu T (1981). Highly sensitive assay for dopamine-beta-hydroxylase activity in human cerebrospinal fluid by high performance liquid chromatography-electrochemical detection: properties of the enzyme. J Neurochem 37 (2 289 296.
30. Moura E, Pinho Costa PM, Moura D, Guimaraes S, Vieira-Coelho MA (2005). Decreased tyrosine hydroxylase activity in the adrenals of spontaneously hypertensive rats. Life Sci 76 (25 2953 2964.
31. Moura E, Afonso J, Hein L, Vieira-Coelho MA (2006). Alpha2-adrenoceptor subtypes involved in the regulation of catecholamine release from the adrenal medulla of mice. Br J Pharmacol 149 (8 1049 1058.
32. Moura E, Afonso J, Serrao MP, Vieira-Coelho MA (2009). Effect of clonidine on tyrosine hydroxylase activity in the adrenal medulla and brain of spontaneously hypertensive rats. Basic Clin Pharmacol Toxicol 104 (2 113 121.
33. Neff NH, Wemlinger TA, Duchemin AM, Hadjiconstantinou M (2006). Clozapine modulates aromatic L-amino acid decarboxylase activity in mouse striatum. J Pharmacol Exp Ther 317 (2 480 487.
34. Neumeister A, Drevets WC, Belfer I, Luckenbaugh DA, Henry S, Bonne O et al. (2006). Effects of a alpha 2C-adrenoreceptor gene polymorphism on neural responses to facial expressions in depression. Neuropsychopharmacology 31 (8 1750 1756.
35. Rosin DL, Melia K, Knorr AM, Nestler EJ, Roth RH, Duman RS (1995). Chronic imipramine administration alters the activity and phosphorylation state of tyrosine hydroxylase in dopaminergic regions of rat brain. Neuropsychopharmacology 12 (2 113 121.
36. Rossetti Z, Krajnc D, Neff NH, Hadjiconstantinou M (1989). Modulation of retinal aromatic L-amino acid decarboxylase via alpha 2 adrenoceptors. J Neurochem 52 (2 647 652.
37. Roth JA (1992). Membrane-bound catechol-O-methyltransferase: a reevaluation of its role in the O-methylation of the catecholamine neurotransmitters. Rev Physiol Biochem Pharmacol 120 : 1 29.
38. Sallinen J, Hoglund I, Engstrom M, Lehtimaki J, Virtanen R, Sirvio J et al. (2007). Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenoceptor antagonist JP-1302. Br J Pharmacol 150 (4 391 402.
39. Scheibner J, Trendelenburg AU, Hein L, Starke K (2001). Alpha2-adrenoceptors modulating neuronal serotonin release: a study in alpha2-adrenoceptor subtype-deficient mice. Br J Pharmacol 132 (4 925 933.
40. Scheinin M, Sallinen J, Haapalinna A (2001). Evaluation of the alpha2C-adrenoceptor as a neuropsychiatric drug target studies in transgenic mouse models. Life Sci 68 (19-20 2277 2285.
41. Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB (2000). A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 275 (30 23059 23064.
42. Soares-da-Silva P, Serrao MP, Vieira-Coelho MA (1996). A comparative study on the synthesis of the natriuretic hormone dopamine in OK and LLC-PK1 cells. Cell Biol Int 20 (8 539 544.
43. Trendelenburg AU, Philipp M, Meyer A, Klebroff W, Hein L, Starke K (2003). All three alpha2-adrenoceptor types serve as autoreceptors in postganglionic sympathetic neurons. Naunyn Schmiedebergs Arch Pharmacol 368 (6 504 512.
44. Vieira-Coelho MA, Soares-da-Silva P (1996). Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone. Br J Pharmacol 117 (3 516 520.
45. Vieira-Coelho MA, Soares-Da-Silva P (1998). Uptake and intracellular fate of L-DOPA in a human intestinal epithelial cell line: Caco-2. Am J Physiol 275 (1 Pt 1 C104 C112.
46. Vieira-Coelho MA, Soares-da-Silva P (1999). Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase. Brain Res 821 (1 69 78.
47. Vieira-Coelho MA, Teixeira VL, Guimaraes JT, Serrao MP, Soares-da-Silva P (1999). Caco-2 cells in culture synthesize and degrade dopamine and 5-hydroxytryptamine: a comparison with rat jejunal epithelial cells. Life Sci 64 (1 69 81.
48. Yavich L, Sirvio J, Haapalinna A, Ylinen A, Mannisto PT (2003). Atipamezole, an alpha2-adrenoceptor antagonist, augments the effects of L-DOPA on evoked dopamine release in rat striatum. Eur J Pharmacol 462 (1-3 83 89.